Tuberculosis Research

Sunday, November 22, 2015

The allies: Rifampicin and Carbapenems

Carbapenems and rifampicin exhibit synergistic activity against M. tuberculosis and M. abscessus in in vitro studies. Click here.

No comments:

WHY IS TUBERCULOSIS IMPORTANT?

Tuberculosis (TB) is an infectious disease caused by 'Mycobacterium tuberculosis'. This bacterium is transmitted when a person with active TB coughs/sneezes. Treatment of TB requires multiple drugs to be taken daily for months. We are slowly losing our arsenal of drugs to treat this global disease. Our mission is to develop a new drug to treat TB.

Click here, here and here to view introductions to clinical TB.

TB DISEASE & RESEARCH

The following interviews (courtesy of TB Alliance) highlight research in TB.

Prof. Stewart Cole

Prof. Michael Iseman

WHO GLOBAL TUBERCULOSIS REPORT

Click here to access the 2013 report

Click here to access the 2012 report
Click here to access their archive

CONTENT ON THIS BLOG

My laboratory focuses on the biology of bacterial peptidoglycan. Therefore, I will post scientific information (ie, publications) that will be LIMITED to this topic. In 2012 I started a research program titled 'Taskforce to study Resistance Emergence & Antimicrobial development Technology' (TREAT). Click here to read more about TREAT.

Here are some protocols (video) from our Center for TB Research.

ABOUT ME

Gyanu Lamichhane: My current efforts are aimed at understanding fundamental biology of the bacterial peptidoglycan layer and to translate these findings to develop inhibitor of biosynthesis of this vital bacterial 'organelle'. I have established a scientific program titled 'Taskforce to study Resistance Emergence & Antimicrobial development Technology' (TREAT) that comprises of multiple labs around the world. Our aim is to understand the genetic and biochemical basis of resistance to B-lactam drugs and to develop more potent drugs of this class. For further information visit http://newantibiotics.blogspot.com/ and http://webhost.nts.jhu.edu/gl/

View my complete profile

FUNDING

Our current work is supported by NIH.

Sunday, November 22, 2015

The allies: Rifampicin and Carbapenems

No comments:

Post a Comment